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Abstract
Background: Generalized anxiety disorder (GAD) is a prevalent mental health condition which is underestimated
worldwide. This study carried out the cultural adaptation into Spanish of the 7-item self-administered GAD-7 scale,
which is used to identify probable patients with GAD.
Methods: The adaptation was performed by an expert panel using a conceptual equivalence process, including
forward and backward translations in duplicate. Content validity was assessed by interrater agreement. Criteria
validity was explored using ROC curve analysis, and sensitivity, specificity, predictive positive value and negative
value for different cut-off values were determined. Concurrent validity was also explored using the HAM-A, HADS,
and WHO-DAS-II scales.
Results: The study sample consisted of 212 subjects (106 patients with GAD) with a mean age of 50.38 years (SD
= 16.76). Average completion time was 2’30’’. No items of the scale were left blank. Floor and ceiling effects were
negligible. No patients with GAD had to be assisted to fill in the questionnaire. The scale was shown to be one-
dimensional through factor analysis (explained variance = 72%). A cut-off point of 10 showed adequate values of
sensitivity (86.8%) and specificity (93.4%), with AUC being statistically significant [AUC = 0.957-0.985); p < 0.001].
The scale significantly correlated with HAM-A (0.852, p < 0.001), HADS (anxiety domain, 0.903, p < 0.001), and
WHO-DAS II (0.696, p > 0.001).
Limitations: Elderly people, particularly those very old, may need some help to complete the scale.
Conclusion: After the cultural adaptation process, a Spanish version of the GAD-7 scale was obtained. The validity
of its content and the relevance and adequacy of items in the Spanish cultural context were confirmed.
Introduction
Anxiety is the manifestation of an emotion where the
individual feels and describes him/herself as restless,
nervous, tense, afraid or excessively worried about speci-
fic, or perhaps undefined, issues [1]. Both the DSM-IV
and the ICD-10 clearly distinguish between generalized
anxiety disorders (GAD) and other anxiety and depres-
sion conditions [2]. While the exact cause of GAD can-
not be specified, there are population groups at greater
risk of suffering it [3-5]. As other anxiety disorders,
GAD is associated to many diseases, both psychiatric
and organic [6]. The impact of GAD on health-related
quality of life is even greater than that observed in
major depression [7], and changes cannot be totally
accounted for by comorbid diseases.
Anxiety disorders are the most common mental disor-
ders in Europe, with a one-year prevalence of 12% in
the European adult population [5], 12-month prevalence
in the adult population of 2% to 3%, and a lifetime pre-
valence of 5% [5]. According to data from the European
Study of the Epidemiology of Mental Disorders
(ESEMeD), conducted in six European countries includ-
ing Spain, the last-year prevalence and the lifetime pre-
valence of anxiety disorders are 6% and 13.6%
respectively [8]. Lifetime prevalence in individuals
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(DSM-IV), and at 6.5% according to the classification
criteria used in Europe (ICD-10) [1,9,10]. It is thought
that more than half the patients with anxiety disorders
attend primary care centers. Since approximately 8% of
these patients are diagnosed with GAD, it follows that
this is the most prevalent anxiety disorder [11,12]. GAD
prevalence in primary care studies carried out in Spain
ranges from 4.5% and 7.9% [1,13].
Nosological changes have led the scientific community
to develop specific, psychometrically sound measure-
ment tools able to identify and quantify the intensity of
GAD according to its current conception, and to assess
the efficacy of psychosocial and psychopharmacological
interventions in these patients. Many health question-
naire-based instruments allowing clinicians to approach
GAD at any healthcare level are currently available.
These tools, or health measurement scales, may be used
for several purposes. They allow for objective quantifica-
tion of the presence and intensity of the main symptoms
of GAD, or may help identify probable cases of GAD.
Scales validated in our culture and routinely used
include the Hamilton Anxiety Scale (HAM-A) [14],
Hospital Anxiety and Depression Scale (HADS) [15],
Covi Anxiety Scale [16], Clinical Anxiety Scale (CAS)
[17], and State-Trait Anxiety Inventory (STAI) [18],
among others. Regardless of whether they are clinician-
administered structured interviews or self-administered
questionnaires to be completed by the patient, all these
scales assess the presence of anxiety symptoms and their
intensity, but are not suitable for early detection or
identification of probable GAD cases by patient self-
administration unless clinically supervised.
Different scales have been developed in recent years in
an attempt to measure the construct of pathological
w o r r y( t h ec o r es y m p t o mo fG A D ) ,o rs i m p l yw o r r y ,a s
an approach to GAD detection, even in the primary
care setting. Only two instruments, the Anxiety Screen-
ing Questionnaire (ASQ-15) [19] and the screening
scale for DSM-IV General Anxiety Disorder of Carroll
and Davidson [20] (the latter based on DSM-IV criteria),
have been designed to evaluate each and every manifes-
tation currently defining GAD. The ASQ-15 allows for
detecting GAD according to DSM-IV and ICD-10 cri-
teria, as well as other anxiety symptoms, but no version
adapted to and validated for our culture is available. On
the other hand, the 12-item Carroll and Davidson scale,
of which a linguistically and psychometrically validated
Spanish version is available [21], allows for identifying
GAD patients according to DSM-IV criteria only.
Recently, a simple 7-item tool, also based on DSM-IV
criteria, has been validated to identify probable cases of
GAD: the GAD-7 scale [22]. This patient- and clinician-
friendly instrument has shown excellent properties to
identify patients with probable GAD, is easy to adminis-
ter, and does not represent an overburden for patients
or clinicians. In addition, its briefness makes it suitable
for use in epidemiological studies and for potential use
in surveys with remote administration of health ques-
tionnaires. No version adapted to our culture is cur-
rently available.
The objective of this study was to create a version of
the GAD-7 questionnaire culturally adapted to the
Spanish language, and to assess the psychometric prop-
erties of the adapted version in terms of reliability and
validity.
Materials and methods
T h eG A D - 7q u e s t i o n n a i r ei sao n e - d i m e n s i o n a ls e l f -
administered scale designed to assess the presence of
the symptoms of Generalized Anxiety Disorder (GAD),
as listed in the DSM-IV. The contents of the question-
naire were selected by the original authors from a larger
list of symptoms. Since the Spanish version has inher-
ited these contents, its content validity is justified by the
original version. Since the objective was to obtain an
instrument as similar to the original as possible, extrac-
tion of additional contents was considered inappropriate.
The methodology currently recommended for adapta-
tion of psychometric instruments was used [23,24];
assumptions of the Classical Test Theory were also used
[25]. The total GAD-7 score is calculated by simple
addition of the answers to each item. Scores for all 7
items range from 0 (Not at all) and 3 (Nearly every
day). Therefore, the total score ranges from 0 and 21.
According to the original authors [22], the total score
may be categorized into four severity groups: minimal
(0-4), mild (5-9), moderate (10-14) and serious (14-20)
[22].
The process of cultural adaptation of the question-
naire started with duplicate translations of the English
original into Spanish by two separate English-speaking
native translators. Both translations were reviewed by an
Expert Panel consisting of 4 clinicians (including a psy-
chiatrist), 1 expert in clinical research, and 2 methodolo-
gists specialized in measurement tasks. Both translations
were then merged into a single reconciled version,
which was subject to a content validity process by inter-
rater agreement estimation. A panel of 8 specialists in
psychiatric disorders was selected for this purpose.
These specialists independently assessed whether each
item did or did not properly measure GAD (objective
concept) and whether it could or could not measure
depression (distractor concept). The index of item-
objective congruence was computed from the specialists’
r a t i n g s[ 2 6 ] .T h i si n d e xh a sav a l u eo f1i nt h ee v e n to f
perfect congruence in assigning the item to one domain,
and a valued of -1 when such congruence is lacking.
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ducted on a reduced sample of patients and control sub-
jects to assess understandability and feasibility of the
translation in real subjects. Completion time was also
estimated. As the questionnaire will be used in the
future to identify possible GAD cases, a subsample of
healthy subjects was included to further assess under-
standability. The reconciled version was administered to
the pilot sample together with a brief additional ques-
tionnaire to ascertain the help needed to complete the
questionnaire, the difficulties encountered, and sociode-
mographic variables. In view of the results obtained in
the pilot test, the questionnaire header was modified to
emphasize the frequency of symptom onset; the anchors
of the response categories were also modified. The final
version was translated back into English by two separate
translators and sent to the original authors for concep-
tual equivalence assessment.
Once piloted, the final version was included in a Case
Report Form (CRF) for administration to the scaling
and validation sample subjects in order to determine the
psychometric properties of the final version. The CRF
included information on disease diagnosis, sociodemo-
graphic variables, disease treatment variables and conco-
mitant diseases, several concurrent questionnaires of
patient-reported measures, and information on the
number of visits to primary care and specialist
physicians.
Study design
This was a multicentre, cross-sectional study to test the
feasibility, reliability, and validity of a new health tech-
nology conducted under standard clinical practice con-
ditions. All patients were required to give their informed
consent to participate in the study and have their data
analyzed. The study protocol was approved by the
Research Committee of the Universidad Autónoma de
Madrid.
Two measurements were performed: (1) Test:a t
recruitment, the GAD questionnaire was administered
to the sample of patients and controls together with
three other instruments: the Hamilton Anxiety Scale
(HAM-A) [14], the Hospital Anxiety and Depression
Scale (HADS) [15], and the WHO-DAS II disability
questionnaire [27,28], all of them in their Spanish ver-
sions (see below). Sociodemographic and medical history
data were recorded at this visit. (2) Retest:o n ew e e k
later, the GAD-7 scale was again administered to a
patient subsample; the retest information was used to
s t u d yt h es t a b i l i t yo fq u e s t ionnaire measurements over
time. The latter was ensured by administering the
HADS concomitantly with GAD-7 one week after the
first administration.
Samples
The pilot sample consisted of 16 subjects selected from
those attending the practices of two of the participating
clinical investigators. Eight patients regularly attending
the practices with a prior diagnosis of clinical GAD
were randomly selected. A sample of 8 GAD-free sub-
jects, sex- and age-matched to patients with GAD, was
also selected.
To obtain the validation and scaling sample, each
investigator had to recruit from 12 to 24 patients, half
of them diagnosed with GAD and the other half as sex-
and age-matched (± 5 years) controls. Patients were ran-
domly selected by 14 investigators (family physicians in
urban areas in the provinces of Madrid, Zaragoza, and
Barcelona) among those attending their practices. Inclu-
sion criteria were as follows: patients of both sexes over
18 years of age; able to speak and understand Spanish;
with a known diagnosis of GAD (for the GAD group of
patients, diagnosis performed under standard medical
practice conditions according to the DSM-IV-TR classi-
fication was required) or no diagnosis of any anxiety dis-
order for control subjects (HAM-A < 10); under no
anxiolytic treatment, or receiving anxiolytic therapy but
with presence of anxiety symptoms (score ≥ 16 points in
the HAM-A anxiety scale) for the GAD group. Exclu-
sion criteria included: patients or subjects who were in a
health state which did not allow for scale self-adminis-
tration in the investigator’s judgment; patients unable to
understand or answer the scale questions due to their
cultural level or knowledge of the Spanish language; or
patients receiving drug treatment likely to interfere with
their ability to understand or answer the scale questions.
Sample size was estimated with respect to sensitivity
of the GAD-7 scale for diagnosing the target disease
(GAD). One hundred participants with GAD were
required to ensure that the total width of the 95% CI
around a sensitivity proportion of 0.90 was no greater
that 0.05, assuming an estimated prevalence of GAD in
clinical populations in Spain ranging from 6% and 8%
[1,8,13]. A similar sized age- and sex-matched control
group was also enrolled. Sample was increased by 5% to
prevent information losses in the statistical analysis. A
total sample size of 210 subjects was therefore consid-
ered adequate.
The retest sample was selected at random as a sub
sample from the scaling and validation sample. Clini-
cians were instructed to repeat the required measures in
the first 2 out of each 10 patients enrolled by her or
him.
Concurrent validity
The following scales were used to assess the concurrent
validity of the adapted version of the GAD-7 scale:
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This is a 14-item, clinician-rated scale formulated as a
semi-structured interview to assess the anxiety level of
the subject. Items are scored from 0 (absent) to 3
(severe). The total score ranges from 0 and 42 points
and may be categorized into four severity groups: nor-
mal (0-9), mild (10-15), moderate (16-24), and severe
(25-42).
Hospital Anxiety and Depression Scale (HADS) [15]
This is a 14-item, self-administered scale in which anxi-
ety and depression are assessed by 7 items each. Each
item is scored from 0 to 3 with several anchors. Some
items are assessed positively and others negatively. A
score ranging from 0 and 21 points may be obtained in
each domain. The score in each domain may be categor-
ized into four severity groups: normal (0-7), mild (8-10),
moderate (15-21) and severe (15-21).
World Health’s Organization Disability Assessment Scale
(WHO-DAS II 12-item version) [27,28]
This is a 12-item, self-administered scale. Items are
grouped by pairs in 6 domains: 1-Understanding and
communicating with the world, 2-Moving and getting
around, 3-Self care, 4-Getting along with people, 5-Daily
life activities (household responsibilities, leisure, and
work), and 6-Participation in society. This scale contains
5 additional items, one about overall health and four
about the number of days with activity limitations in
daily life. Scoring is standardized on a 0-100 metric
scale, where 0 means no disability and 100 the highest
disability.
Statistical analysis and psychometric studies
A descriptive analysis including measures of central ten-
dency and dispersion and Gaussian curve fitting using a
Kolmogorov-Smirnov test was first performed. The
study of the psychometric properties of the GAD-7 scale
focused on three aspects: feasibility, reliability, and valid-
ity. Feasibility: this section recorded the time taken by
patients to complete the scale, the difficulties encoun-
tered by patients for answering questions, and the num-
ber of missing values (non-answering patients) for each
question. Items were analyzed by calculating the fre-
quency of each response category within each item, as
well as the blank response rate for each item. Floor and
ceiling effects were also analyzed, both in each item and
in the overall questionnaire. Reliability: reliability was
assessed by Cronbach’s alpha calculation [29] for inter-
nal consistency, and by test-retest stability estimation
using the correlation between presentations and the
intra-class correlation coefficient. Validity: (a) Construct:
structural validity (or construct validity) was assessed by
exploratory factor analysis [30] using the common factor
model, the principal component extraction method, and
Oblimin rotation (if rotation was possible). The K1 rule
(eigenvalues greater than one) and Cattell’s screen test
were used to decide on the number of factors contained
in the solution. A confirmatory factor analysis [31,32]
was also performed to corroborate the original structure,
assuming the existence of one single factor where all
items loaded. The maximum likelihood estimation
method was used by means of LISREL 8.8 software. (b)
Discriminant validity: discriminant validity was calcu-
lated by dividing the sample into quartiles based on the
GAD-7 total score and comparing the upper to the
lower quartile, both for the mean scores in individual
items and for the overall score. For other clinical cri-
teria, validity was assessed by calculating the mean-
related difference between the GAD-7 mean overall
score of the diagnostic groups assigned by the clinical
investigator, A Student’s t-test, Mann-Whitney’sUt e s t
for independent groups, or one-way ANOVA were used,
depending on the number of groups compared. (c) Cri-
terion validity: diagnostic performance curves (ROC
curves) were analyzed, and sensitivity and specificity
rates, as well as the positive and negative predictive
values of the questionnaire, were calculated when the
resulting diagnostic classification was compared to the
clinical diagnosis of reference. (d) Convergent validity:
The degree of concordance between the GAD-7 scale
and the Hamilton Anxiety Scale (HAM-A), the Hospital
Anxiety and Depression Scale (HADS, anxiety domain),
and the WHO-DAS II disability questionnaire was cal-
culated. Concordance between classification criteria was
assessed by inter-rater agreement statistics (kappa) and
a Chi-square test.
All statistical calculations were performed using SPSS
for Windows v15.0 routines.
Results
The pilot sample included 62.5% of males with a mean
age of 50.38 years (SD = 16.76 years, min = 32, max =
83). Among these, 28.6% had primary education, 42.9%
secondary education, 14.3% higher education or voca-
tional training, and 14.3% had finished a degree. Mean
questionnaire completion time was 2 minutes and 30
seconds (SD = 0:01:24), with values ranging from 5 min-
utes in one subject and 30 seconds in two subjects. No
items in the questionnaire were left blank, and no
response accumulation at the ends of the scale was
observed. No patient diagnosed with GAD asked for any
help from the clinician in charge or needed any clarifi-
cation. In the control group, an 83-year-old woman
reported that she needed help to answer the question-
naire because she did not know where to mark the
answers. Three control subjects reported difficulty in
answering some of the questions, particularly question
5. Only the 83-year-old woman reported having asked
for clarifications. An initial check in the pilot sample of
item discrimination ability between patients and
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icant differences between groups (p < 0.05), except for
item 5 (p = 0.105).
A total of 212 patients with full information were
recruited for the validation and scaling sample. Mean
patient age was 47.59 years (SD = 15.8), with values ran-
ging from 19 and 85 years, and 72.6% of patients were
female. Mean body mass index (BMI) of sample patients
was 25.97 (SD = 4.5) kg/m
2,w i t hv a l u e sr a n g i n gf r o m
16.53 and 45.7. Ninety-nine percent of patients were
Caucasian and only 1% were black. Four percent had
not finished elementary school, while 33% had finished
elementary school, 27% secondary school, 15% voca-
tional training, and 21% higher education. As regards
marital status, 17% were single, 66% married, 8%
divorced or separated, 8% widowed, and 1% other. As to
occupational status, 20% of patients were housewives,
61% were working, 4% unemployed, 6% occupationally
disabled, and 9% retired.
According to the initial sample design, 50% of patients
belonged to the group diagnosed with GAD and 50% to
the control group. Sex- and age-matching of both sub
samples was verified. The difference between mean ages
in both groups was 0.9 years (SE = 2.18), which was
considered non-significant (p = 0.679). No significant
differences were also found in all other sociodemo-
graphic variables: sex (p = 1.00); race (p = 0.161); level
of education (p = 0.262); marital status (p = 0.596);
occupational status (p = 0.095).
As expected, a significant difference was found
between the clinical and control groups in ongoing
treatment. Seventy-nine percent of patients in the GAD
group and only 20% in the control group were receiving
any treatment (p < 0.001). Patients in the GAD group
had a maximum of 6 treatments, although most patients
had 1 or 2 treatments. Twenty-nine GAD patients were
receiving no treatment. In the group diagnosed GAD,
the duration of disorder ranged from 0 and 22 years,
with a mean of 3 and a half years (SD = 3.9). The most
commonly used treatments included SSRI and SNRI
antidepressants (44%), followed by long-term (34%) or
short-term (28%) benzodiazepines.
Feasibility
All subjects answered all questions in the GAD-7 ques-
tionnaire, i.e. no blanks were recorded. Hence, there
seems to be neither item comprehension problems nor
likelihood of inadequate choice of the terms used as
response scale anchor points in the adapted question-
naire. Completion time was short (around 2 and half
minutes). Overall, answers were suitably distributed
throughout all answer categories. There was a slight ten-
dency to a floor effect in questions 4 (worried about dif-
ferent things) and 7 (afraid as if something awful might
happen), with 42% and 51% accumulation of answers in
the lowest rating ("not at all”) respectively. Because scale
assessment is performed with both GAD and control
subjects, these two items may be considered as particu-
larly “difficult” to comply with in the absence of GAD.
All items showed some degree of positive asymmetry,
with a tendency for answers to accumulate in the lowest
rating categories; however, answer distribution in items
1 through 4 may be considered symmetric.
Dimensionality and scaling
In the exploratory factor analysis, only an eigenvalue
greater than one was obtained, which would account for
the 72% variance found in the correlation matrix. All
items had positive loadings higher than 0.75 in the sin-
gle domain (Table 1), and the proportion of explained
variance from each individual item (communality) ran-
g e df r o m0 . 5 7 6( i t e m6 )a n d0 . 7 9 8( i t e m s1a n d3 ) .
S i n c eo n l yo n ed o m a i nw a so btained, the solution was
not rotated.
The confirmatory factor solution obtained (Figure 1)
produced a good fit, with a Chi-square/df ratio value of
2.8, i.e. lower than 3, as recommended [33]. GFI statis-
tics reached a value of 0.96 (> 0.95), AGFI = 0.91 (>
0.90), CFI = 0.99 (> 0.90), NFI = 0.98 (> 0.90), and
RMSEA = 0.080 (≤0.080). All estimated loadings were
s i g n i f i c a n t( p<0 . 0 0 1 ) ,t h es i g no b t a i n e dw a sa s
expected, and the model was correctly identified.
Reliability
Cronbach’s alpha reached an excellent value (0.936). All
items showed a high item-total correlation (higher than
0.68), with a test-retest correlation of 0.844 and an
intra-class correlation coefficient of 0.926 (95% confi-
dence interval of 0.881-0.958). Comparative values
obtained with HADS yielded a Cronbach’s alpha at base-
line of 0.820 (considered to be a good value), with a
test-retest correlation of 0.938 and an intra-class corre-
lation coefficient of 0.926 (95% confidence interval of
0.881-0.959).
Inter-rater validity
All items reached the highest score for the congruence
index in the GAD objective domain, with scores ranging
from 0.50 (item 7) and the maximum possible value of 1
Table 1 GAD-7 scale item loading in the 1 component
exploratory factor solution and explained variance.
Item Component
Nervous 0.893
Stop worrying 0.880
Excessively worried 0.893
Restless 0.870
Difficulty in relaxing 0.840
Easily irritated 0.757
Afraid of something awful 0.811
Explained variance 72,341
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in all cases in the depression domain, with values ran-
ging from -0.31 (item 7) and -0.75 (item 5). These
results suggest that all items adequately measure the
GAD concept. Although all congruence scores in the
depression distractor domain were negative, the fact
that three of the scores were somewhat distant from -1
(within -0.31 and -0.38) suggests that raters think that
the corresponding items might also indicate the pre-
sence of some degree of depression, but always tangen-
tially, since all items reach the maximum possible rating
in the anxiety domain.
Discriminant validity
The scores obtained with the selected sample covered
the whole possible metric space, and scores of both 0
and 21 points were recorded. Mean score was 8.75
points, with a standard deviation of 6.44 points. The
95% confidence interval for the mean ranged from 7.88
and 9.62. Skewness statistics did not suggest lack of
symmetry (skewness = 0.167; SE = 0.167), but visual
inspection of score distribution suggested a slight posi-
tive bias, thus ruling out a normal distribution (K-S =
0.144; DF = 212; p < 0.001). This lack of normality may
be attributed to the existence of two scoring subgroups
(normal subjects and GAD subjects), assumed to origi-
nate from different reference populations.
When quartiles 1 and 4 were compared, all items
yielded significant differences (p < 0.001) in all cases;
variance was also different between the two groups in
all items (p < 0.08). it may thus be concluded that each
and every item is able to discriminate between high and
low scores, and contributes to them.
The total GAD-7 score detected significant differences
between the means recorded for the group diagnosed
G A D( m e a n=1 3 . 9 6 ,S D=4 . 1 9 )a n dt h ec o n t r o lg r o u p
(mean = 3.54, SD = 3.32). The difference between the
groups was significant (p < 0.001) and a trend towards
different group variances was also suggested (p = 0.070).
Criterion validity
Since the area under the receiver operating characteris-
tic curve (ROC curve) reached a value of 0.957 (SE =
0.014, p < 0.001), the null hypothesis of the area having
a value of 0.5 in the population (and thus indicating the
absence of inter-group discrimination) can be rejected.
The 95% confidence interval ranged from 0.930 and
0.985, thus suggesting excellent discrimination. Use of a
score of 10 as cut-off point resulted in a sensitivity of
86.8% and a specificity of 93.4%. Positive and negative
predictive values were 92.9% and 87.6% respectively
(Table 2). Figure 2 shows the ROC curves for the scores
of GAD-7 and the concurrent measures. Areas under
the curve with 95% confidence intervals for each indivi-
dual measure follow. HADS-Anxiety: 0.942 (0.911-
0.974), Hamilton: 0.970 (0.945-0.944), and WHO-DAS:
0.868 (0.820-0.916). Confidence intervals for GAD-7,
HADS, and Hamilton overlapped, and should therefore
not be considered statistically different. The WHO-DAS
II scale showed a comparatively worse discriminant
behavior.
The score obtained in GAD-7 significantly correlated
with the other questionnaires used in the study as con-
current measures (Table 3). A very high correlation was
seen between GAD-7 and the HADS Anxiety scale (r =
Figure 1 Maximum likelihood confirmatory solution of items in
the adapted version of the GAD-7 scale. Standardized loadings.
Chi-Square = 32.59, df = 14, p-value = 0.00330, RMSEA = 0.080
Table 2 Operating characteristics of GAD-7 for different
cut-off points.
Cut-off point Sensitivity Specificity PPV NPV Cases
8 93.4 85.8 88.6 92.9 53.8
9 91.5 90.6 90.7 91.4 50.5
10 86.8 93.4 92.9 87.6 46.7
11 79.2 95.3 94.4 82.1 42.0
12 74.5 96.2 95.2 79.1 39.2
13 67.9 97.2 96.0 75.2 35.4
14 62.3 100.0 100.0 72.6 31.1
Note: PPV = Positive predictive value; NPV = Negative predictive value. All
values expressed as %.
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depression scale (r = 0.713). Since a possible overlap of
the depression and anxiety subscales and GAD-7 was
suspected, an exploratory factor analysis was conducted
with all items of both scales, which resulted in two dif-
ferentiated factors: one containing all GAD-7 items plus
items in the HADS Anxiety subscale, and the other con-
taining the items in the HADS Depression subscale.
The comparison of the GAD-7 scores of the four sever-
ity groups of anxiety diagnosed by the HADS-A yielded
significant differences between the mean group scores (F
=2 0 5 . 3 ;D F 1=3 ;D F 2=2 0 8 ;p<0 . 0 0 1 ) .D i f f e r e n tv a r -
iances among groups were also seen (F = 3.64; DF1 = 3;
DF2 = 208; p = 0.014). All severity groups had significantly
different (p < 0.001) mean GAD-7 scores. Furthermore,
there was agreement between the classification groups
generated by both scales (Kappa = 0.493; p < 0.001).
A high correlation (r = 0.852) was also found between
GAD-7 and the Hamilton Anxiety Scale (HAM-A)
(Table 3). Differences were seen between the classifica-
tion groups based on HAM-A in the mean values in the
GAD-7 scale (F = 175.3; DF1 = 3; DF2 = 208; p < 0.001)
and variances (F = 3.24; DF1 = 3; DF2 = 208; p = 0.023)
(Figure 3). Multiple intergroup comparisons showed sig-
nificant differences between all severity groups (p <
0.007). There was agreement between the classification
groups generated by both scales (Kappa = 0.502; p <
0.001).
GAD-7 correlation with the WHO’s Disability Assess-
ment Scale was high and positive (Table 4), although
somewhat lower (r = 0.704) than other concurrent cor-
relations. Significant between-group differences were
found (p < 0.001) when the total DAS scores of the con-
trol and GAD groups were compared. Significant differ-
ences were also found for all 6 DAS domains; higher
disability scores were recorded in the group diagnosed
GAD (Figure 4). While the GAD-7 scores showed differ-
ent degrees of correlation with the different DAS
Figure 2 ROC curve of GAD-7 total score.
Table 3 Correlation of GAD-7 with other concurrent questionnaires used in the cultural adaptation study of the scale.
GAD - Total score Anxiety (HADS) Depression (HADS) Hamilton-A
Anxiety (HADS) .903** - - -
Depression (HADS) .713** .733** - -
Hamilton (A) .852** .835** .760** -
WHO-DAS Total score .704** .753** .813** .755**
** p < 0.001
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Page 7 of 11domains (Table 4), all of them were significant (p <
0.001). The highest correlations were observed in the
Participation in society (r = 0.741), Understanding and
communicating with the world (r = 0.679), and Life
activities (r = 0.638) domains, while the lowest ones
were found in the Self care (r = 0.412) and Moving and
getting around (r = 0.438) domains. GAD-7 scores sig-
nificantly correlated (p < 0.001) with the number of
days with activity limitations in daily life (r = 0.686) and
with the number of days in which the patient was
unable to carry out his/her tasks (r = 0.454). Similarly,
significant albeit moderate correlations were found in
the number of times patients has attended medical visits
(either to primary care or specialist physicians) in the
previous 4 weeks (Table 4).
Discussion
The version adapted into Spanish of the GAD-7 scale
has a one-dimensional structure that matches the origi-
nal structure based on DSM-IV diagnostic criteria. All
items measure the same concept and in the same direc-
tion. Excellent reliability values were found both for
homogeneity in concept measurement and stability
between measurements when no clinical intervention
was involved. The expert panel agreed that the construct
assessed by the questionnaire was eminently one-dimen-
sional and distinguishable from depression-related
symptoms. In addition, the scores for the scale corre-
lated well with those of other scales assessing anxiety,
particularly the rater-administered HAM-A and the self-
administered HADS. It must be taken into account that
GAD patients also have symptoms of depression,
although both conditions are discernible.
Each individual item in the scale, as well as the total
score, adequately discriminated between control subjects
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Figure 3 Mean and confidence interval (95%) of HAM-A score by severity group according to the GAD-7 scale. Anxiety group according
to GAD-7 score; Normal/Minimum (0-7 points), Mild (8-10), Moderate (11-14) and Severe (15-21). p < 0.001 for between-group comparisons in all
cases. Diagonal segments are produced by ties.
Table 4 Correlation of GAD-7 with scores (total and by
domain) in the WHO-DAS II disability assessment scale
and with the number of medical visits (to primary care
and specialist physicians) in the past 4 weeks.
WHO-DAS II GAD-7
Total score .696**
Understanding and communicating with the world .679**
Moving and getting around .438**
Self care .412**
Getting along with people .585**
Daily life activities .638**
Participation in society .741**
Medical visits GAD-7
Primary care .393**
Specialist .373**
** p < 0.001
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ical criteria. Since a cut-off point of 10 yields excellent
sensitivity and specificity values, and is in line with the
cut-off value proposed by the original authors of the
scale [22], this value is proposed for potential GAD
diagnosis in standard clinical practice.
As noted by Spitzer et al. during the development of
the original instrument [22], a relationship was also
found between GAD assessments using the scale and
the disability level assessed by the WHO-DAS II scale in
several domains of daily life. This agrees with previous
observations relating GAD to a high disability level in
terms of work and daily life activities [5,34,35]. In addi-
tion, the group diagnosed GAD had the greatest number
of ongoing treatments and a greater number of disability
days experienced.
The GAD-7 scale adapted into Spanish has been
shown to correlate well with two scales widely used to
assess severity of anxiety symptoms in our setting and
in other clinical environments. These scales, i.e. HAM-A
administered by a trained interviewer or HADS self-
administered by the patients, are used in daily clinical
practice as GAD diagnostic support to assess symptom
severity and to monitor the impact of healthcare inter-
ventions on this disorder. While not properly analyzed
in this cultural adaptation study, future uses of the
GAD-7 scale similar to those of HAM-A and HADS
should not be dismissed. Indeed, the good performance
of the new scale and its short administration time
should be advantageous and provide for highly cost-
effective administration. In fact, the cut-off points set to
separate categories of symptom severity fully agree with
those set for the HAM-A and HADS scales. It should be
kept in mind that the original purpose of the GAD-7
scale was to screen patients suffering from this condi-
tion. While psychometric scaling properties and validity
measures are promising, additional evidence will be
needed in order to fully enable its use as a patient
reported outcome measure. A literature review found no
information about the meaningful clinical difference or
the change expected in scores in follow-up studies.
While our adaptation study may have limitations,
some of these should be attributed to the scale itself,
rather than to the cultural adaptation study. Thus, in
line with the comments issued during the scale pilot
test, the questionnaire correction manual should include
a warning on its use in elderly populations, emphasizing
the possible need for clarification support or help when
questions are read by patients, particularly very old
patients. Because our study was conducted in medical
centers representative of three autonomous commu-
nities only, its generalization to other cultural environ-
ments might be questioned. However, we think that the
participating centers from Madrid, Barcelona, and Sara-
gossa may be representative of the linguistic variability
existing in the country, and may therefore be sufficiently
representative of the whole national territory. However,
use of this scale in Spanish-speaking environments cul-
turally different from Spain should be tested in advance
using appropriate psychometric studies.
In conclusion, the version adapted into Spanish
showed excellent metric properties, and its high discri-
minant ability, briefness, and fast administration allow
for its use in standard clinical practice for patient
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Figure 4 Mean (95% CI) standardized score of WHO DAS II scale, total and by domain, by group of subjects. GAD = Generalized Anxiety
Disorder group; Control = Control group; **p < 0.001.
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Page 9 of 11screening purposes. The ability of the scale to measure
changes in patient conditions over time, or in response
to treatment, remains to be elucidated. We hope that
availability of this questionnaire to Spanish-speaking
healthcare professionals will allow for increasing early
detection and treatment of these patients, thus improv-
ing their quality of life and reducing medical and psy-
chiatric complications.
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